Compare Atmos Energy Corporation (ATO) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atmos Energy Corporation vs Mesoblast Limited — how do they compare? Atmos Energy Corporation trades at $178.45 (market cap $29.79B), while Mesoblast Limited trades at $17.61 (market cap $2.12B). The key difference: Atmos Energy Corporation is far larger — about 14.1× Mesoblast Limited's market cap, and Atmos Energy Corporation pays a 2.24% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| ATO | MESO | |
|---|---|---|
Market Cap | $29.79B | $2.12B |
Sector | Utilities | Technology |
52-Week High | $192.25 | $20.96 |
52-Week Low | $154.10 | $10.96 |
Enterprise Value | $39.29B | $2.13B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atmos Energy (ATO) trades at $179.50, up 1.87% on the day, with a bullish technical outlook and strong support near $179. The stock shows solid fundamentals with a P/E of 22.11, revenue of $4.70B in 2025, and net income margin of 27.58%. Recent news highlights its position to benefit from data center demand and regulatory support, with an upcoming Q3 earnings call on August 6, 2026.
The outlook is positive with a consensus price target of $191.00, though risks include high capital expenditures and debt levels. Earnings growth and dividend stability provide upside, but investors should monitor execution on capex plans and interest rate impacts.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
